Phase 2 N=18 Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
Carcinoma, Non Small Cell Lung
Primary: Three-month Progression-free Survival — 11.1 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=411 On Versus Off Pump Myocardial Revascularization Study
Coronary Artery Disease
Primary: Number of Patients With Post-operative Combined Endpoint (i.e. With One or More of the Following) — 13; 26 participants
Phase 2 N=73 Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury
Prostate Cancer
Primary: Percentage of Participants With Physician Reported Rectal Toxicity ≥ Grade 2 During the First 2 Years of Radiation Treatment — 38 percentage of participants — p=0.9138
N/A N=162 Safety and Efficacy Study of BondEase to Treat Traumatic Lacerations and Surgical Incisions
Traumatic Lacerations or Surgical Incisions
Primary: 100% Wound Apposition at 10 Days — 77.1; 80.4 percentage of participants
Phase 4 N=10 Effects of Kuvan on Melatonin Secretion
Phenylketonuria (PKU)
Primary: Serum Melatonin at the End of 4 Weeks — 266.9; 205.7; 220.4; 301.2 pg/ml
Phase 1 N=84 Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Abnormal Physical Examination Findings
Phase 4 N=87 Efficacy of Fish Oil in Lupus Patients
Systemic Lupus Erythematosus
Primary: Effect on Brachial Artery Flow Dilation by Omega-3 Versus Placebo. — 0.32; 0.33; 0.32; 0.33 cm — p=0.87
Phase 4 N=41 The Effect of Linagliptin on Mitochondrial and Endothelial Function
Type II Diabetes Mellitus
Primary: Phosphocreatine (PCR) Recovery Time After Exhaustive or up to 6 Minutes of Leg Exercise. — 0.0; 1.01 seconds — p=>0.05
Phase 2 N=54 Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Arthroplasty (TKA)
Knee Pain
Primary: Participants With Clinically Meaningful Improvement in Pain Severity (0-10 cm; Higher Score on Pain Scale is Worse) — 15; 9 participants
N/A N=35 A Clinical Study of Systane® Lid Wipes in Brazil
Ocular Tolerance · Skin Tolerance
Primary: Number of Participants With a Contact-dermatitis Adverse Reaction — 0 participants
Phase 1 N=34 The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)
Hepatic Insufficiency
Primary: Area Under the Curve From 0 to Infinity (AUC0-inf) of Elbasvir — 1.56; 1.86; 2.28; 2.58 μM•hr
N/A N=397 Study of the Safety and Effectiveness of the Artificial Cervical Disc - Low Profile Device at Two Adjacent Levels
Cervical Degenerative Disc Disease · Radiculopathy · Myelopathy
Primary: Rate of Overall Success — 81.4; 69.4 percentage of participants — p=1.000
Phase 4 N=34 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
N/A N=390 Impact of Helmet Use in Preschool Children
Head Injuries · Facial Injuries
Primary: Percentage of Participants Wearing Helmet — 65.6; 49.3; 80.5; 62.2 Percentage of Participants — p=<0.01
Phase 4 N=166 Local Anesthesia Versus Saline Serum in Surgical Incision of Colorectal or Hepatic Surgery
Postoperative Pain · Surgery · Postoperative Complications
Primary: Mg of Morphine Consumption During 48 Hours Administered by Patient Controlled Analgesia System — 23; 52; 24.63; 26.78 mg